Another cPLA2 inhibitor, 4-[2-[5-chloro-1-(diphenylmethyl)-2-methyl-1H-indol-3-yl]-ethoxy]benzoic acid (CDIBA), has been used to demonstrate key regulatory roles of cPLA2 and lysophospholipids in brain and lung cancers in vivo [25], and cPLA2α inhibitors (e.g., AVX001, AVX002, AVX235) developed by Avexxin, now Coegin Pharma, were previously shown to inhibit inflammation [28,29,30,31,32,33], tumor progression, and angiogenesis both in vitro and in vivo [34,35]. This evidence concerns the gene PLA2G4A and lung cancer.